Doxorubicin enhances CD4(+) T-cell immune responses by inducing expression of CD40 ligand and 4-1BB
- Authors
- Park, Jae Yeo; Jang, Min Ja; Chung, Yoon Hee; Kim, Kyung Yong; Kim, Sung Su; Lee, Won Bok; You, Seungkwon; Choi, Youn Seok; Hur, Dae Young; Kim, Daejin
- Issue Date
- Dec-2009
- Publisher
- ELSEVIER SCIENCE BV
- Keywords
- Doxorubicin; CD4; CD40 ligand; 4-1BB
- Citation
- INTERNATIONAL IMMUNOPHARMACOLOGY, v.9, no.13-14, pp.1530 - 1539
- Indexed
- SCIE
SCOPUS
- Journal Title
- INTERNATIONAL IMMUNOPHARMACOLOGY
- Volume
- 9
- Number
- 13-14
- Start Page
- 1530
- End Page
- 1539
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/118801
- DOI
- 10.1016/j.intimp.2009.09.008
- ISSN
- 1567-5769
- Abstract
- Chemotherapy agents have adverse immunotherapeutic effects secondary to inhibition of hematopoietic stem cell proliferation, particularly in committed lymphoblast. Certain anti-cancer drugs have immunomodulatory properties, although mechanisms are still not fully understood. In the current study, we explored the effects of doxorubicin on peripheral blood CD4(+) and CD8(+) T-cell responses pre- and post-siimulation. Doxorubicin treatment alone had no effects on peripheral blood T lymphocytes and regulatory T-cells in vivo and in vitro. However, CD4(+) T-cells were resistant to doxorubicin and demonstrated more robust proliferation than CD8(+) T-cells after doxorubicin pre-treatment. CD40 ligand and 4-1BB expression on the surface of CD4(+) T-cells were increased after TCR-ligation activation; however, expression on CD8(+) T-cells was not increased. Dendritic cells cultured in the presence of activated CD4(+) T-cells pre-treated with doxorubicin had greater survival rates than those cultured with activated CD8(+) T-cells. Doxorubicin pre-treatment followed by anti-CD3 epsilon + anti-4-1BB activation led to proliferation of CD4(+) T-cells and no proliferative effects on CD8(+) T-cells. Our results collectively suggest that doxorubicin pre-treatment in cancer patients may be a more effective way to enhance anti-cancer immune responses by increased antigen-specific CD4(+) Th1 immune responses. (C) 2009 Elsevier B.V. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biotechnology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.